Skip to main content

X-linked Retinoschisis

3
Pipeline Programs
4
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Beacon Therapeutics
Beacon TherapeuticsMA - Cambridge
2 programs
1
rAAV2tYF-CB-hRS1Phase 1/21 trial
Dorzolamide 2% TID or brinzolamide 1% TIDN/A1 trial
Active Trials
NCT02331173Completed66Est. Oct 2016
NCT02416622Completed27Est. May 2023
Atsena Therapeutics
1 program
1
ATSN-201Phase 1/21 trial
Active Trials
NCT05878860Recruiting97Est. Apr 2033
Zhongmou Therapeutics
1 program
1
ZM-01-LPhase 11 trial
Active Trials
NCT06066008Completed2Est. Jan 2026
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
LX103 InjectionN/A1 trial
Active Trials
NCT05814952Recruiting12Est. Aug 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Atsena TherapeuticsATSN-201
Beacon TherapeuticsrAAV2tYF-CB-hRS1
Zhongmou TherapeuticsZM-01-L
BioTherapeutics IncLX103 Injection
Beacon TherapeuticsDorzolamide 2% TID or brinzolamide 1% TID

Clinical Trials (5)

Total enrollment: 204 patients across 5 trials

NCT05878860Atsena TherapeuticsATSN-201

ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Start: Aug 2023Est. completion: Apr 203397 patients
Phase 3Recruiting
NCT02416622Beacon TherapeuticsrAAV2tYF-CB-hRS1

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

Start: May 2015Est. completion: May 202327 patients
Phase 1/2Completed
NCT06066008Zhongmou TherapeuticsZM-01-L

Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients

Start: Sep 2022Est. completion: Jan 20262 patients
Phase 1Completed
NCT05814952BioTherapeutics IncLX103 Injection

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

Start: Dec 2022Est. completion: Aug 202812 patients
N/ARecruiting
NCT02331173Beacon TherapeuticsDorzolamide 2% TID or brinzolamide 1% TID

Clinical Evaluation of Patients With X-linked Retinoschisis

Start: Nov 2012Est. completion: Oct 201666 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 204 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.